JP2013516463A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013516463A5 JP2013516463A5 JP2012547986A JP2012547986A JP2013516463A5 JP 2013516463 A5 JP2013516463 A5 JP 2013516463A5 JP 2012547986 A JP2012547986 A JP 2012547986A JP 2012547986 A JP2012547986 A JP 2012547986A JP 2013516463 A5 JP2013516463 A5 JP 2013516463A5
- Authority
- JP
- Japan
- Prior art keywords
- patient
- content
- amino acid
- composition
- glucose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 235000001014 amino acid Nutrition 0.000 claims description 146
- 229940024606 amino acid Drugs 0.000 claims description 146
- 150000001413 amino acids Chemical class 0.000 claims description 146
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 133
- 239000008103 glucose Substances 0.000 claims description 133
- 238000001802 infusion Methods 0.000 claims description 107
- 239000000203 mixture Substances 0.000 claims description 101
- 230000037396 body weight Effects 0.000 claims description 100
- 150000002632 lipids Chemical class 0.000 claims description 61
- 238000001631 haemodialysis Methods 0.000 claims description 36
- 230000000322 hemodialysis Effects 0.000 claims description 36
- 150000005693 branched-chain amino acids Chemical class 0.000 claims description 18
- 208000002720 Malnutrition Diseases 0.000 claims description 15
- 230000001071 malnutrition Effects 0.000 claims description 15
- 235000000824 malnutrition Nutrition 0.000 claims description 15
- 208000015380 nutritional deficiency disease Diseases 0.000 claims description 15
- 238000000502 dialysis Methods 0.000 claims description 13
- 239000008280 blood Substances 0.000 claims description 12
- 210000004369 blood Anatomy 0.000 claims description 12
- 238000007911 parenteral administration Methods 0.000 claims description 11
- 102000009027 Albumins Human genes 0.000 claims description 10
- 108010088751 Albumins Proteins 0.000 claims description 10
- 238000005259 measurement Methods 0.000 claims description 9
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 6
- 239000002552 dosage form Substances 0.000 claims description 6
- 238000011282 treatment Methods 0.000 claims description 6
- 150000001720 carbohydrates Chemical class 0.000 claims description 5
- 235000014633 carbohydrates Nutrition 0.000 claims description 5
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims description 3
- 239000004475 Arginine Substances 0.000 claims description 3
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 3
- 239000004471 Glycine Substances 0.000 claims description 3
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims description 3
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 3
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims description 3
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 3
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 3
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims description 3
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 3
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 3
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 3
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 3
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims description 3
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims description 3
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims description 3
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 3
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 3
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 3
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 3
- 239000004472 Lysine Substances 0.000 claims description 3
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims description 3
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 3
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims description 3
- 239000004473 Threonine Substances 0.000 claims description 3
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims description 3
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims description 3
- 235000004279 alanine Nutrition 0.000 claims description 3
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 3
- 235000003704 aspartic acid Nutrition 0.000 claims description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 3
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims description 3
- 206010012601 diabetes mellitus Diseases 0.000 claims description 3
- 235000013922 glutamic acid Nutrition 0.000 claims description 3
- 239000004220 glutamic acid Substances 0.000 claims description 3
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 3
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims description 3
- 229960000310 isoleucine Drugs 0.000 claims description 3
- 229930182817 methionine Natural products 0.000 claims description 3
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims description 3
- 235000013930 proline Nutrition 0.000 claims description 3
- 235000004400 serine Nutrition 0.000 claims description 3
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 3
- 235000002374 tyrosine Nutrition 0.000 claims description 3
- 239000004474 valine Substances 0.000 claims description 3
- 239000000243 solution Substances 0.000 claims 12
- SBAJRGRUGUQKAF-UHFFFAOYSA-N 3-(2-cyanoethylamino)propanenitrile Chemical compound N#CCCNCCC#N SBAJRGRUGUQKAF-UHFFFAOYSA-N 0.000 claims 1
- 239000007864 aqueous solution Substances 0.000 claims 1
- 235000016236 parenteral nutrition Nutrition 0.000 claims 1
- 238000011321 prophylaxis Methods 0.000 claims 1
- 238000000034 method Methods 0.000 description 85
- 210000001124 body fluid Anatomy 0.000 description 8
- 239000010839 body fluid Substances 0.000 description 8
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 230000007423 decrease Effects 0.000 description 3
- 239000011785 micronutrient Substances 0.000 description 3
- 235000013369 micronutrients Nutrition 0.000 description 3
- 208000019901 Anxiety disease Diseases 0.000 description 2
- 208000000059 Dyspnea Diseases 0.000 description 2
- 206010013975 Dyspnoeas Diseases 0.000 description 2
- 206010019909 Hernia Diseases 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 208000037656 Respiratory Sounds Diseases 0.000 description 2
- 230000036506 anxiety Effects 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 201000001421 hyperglycemia Diseases 0.000 description 2
- 206010037833 rales Diseases 0.000 description 2
- 230000036387 respiratory rate Effects 0.000 description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- LKDRXBCSQODPBY-AMVSKUEXSA-N L-(-)-Sorbose Chemical compound OCC1(O)OC[C@H](O)[C@@H](O)[C@@H]1O LKDRXBCSQODPBY-AMVSKUEXSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- 239000005441 aurora Substances 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US29213910P | 2010-01-04 | 2010-01-04 | |
| US61/292,139 | 2010-01-04 | ||
| US29280610P | 2010-01-06 | 2010-01-06 | |
| US61/292,806 | 2010-01-06 | ||
| PCT/US2010/003192 WO2011081660A1 (en) | 2010-01-04 | 2010-12-15 | Nutritive compositions and methods of using same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013516463A JP2013516463A (ja) | 2013-05-13 |
| JP2013516463A5 true JP2013516463A5 (enExample) | 2014-02-06 |
Family
ID=44226741
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012547991A Active JP5774603B2 (ja) | 2010-01-04 | 2010-07-30 | 栄養組成物およびその使用方法 |
| JP2012547986A Pending JP2013516463A (ja) | 2010-01-04 | 2010-12-15 | 栄養組成物およびその使用方法 |
| JP2015094645A Pending JP2015187112A (ja) | 2010-01-04 | 2015-05-07 | 栄養組成物およびその使用方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012547991A Active JP5774603B2 (ja) | 2010-01-04 | 2010-07-30 | 栄養組成物およびその使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015094645A Pending JP2015187112A (ja) | 2010-01-04 | 2015-05-07 | 栄養組成物およびその使用方法 |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US8927505B2 (enExample) |
| EP (2) | EP2521559A4 (enExample) |
| JP (3) | JP5774603B2 (enExample) |
| KR (2) | KR20120125487A (enExample) |
| CN (2) | CN102883729A (enExample) |
| AU (2) | AU2010337355A1 (enExample) |
| BR (2) | BR112012016435A2 (enExample) |
| CA (2) | CA2786375A1 (enExample) |
| GB (2) | GB2489163A (enExample) |
| IL (1) | IL220715A0 (enExample) |
| MX (2) | MX2012007704A (enExample) |
| NZ (2) | NZ601027A (enExample) |
| WO (2) | WO2011081679A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100137693A1 (en) * | 2005-11-01 | 2010-06-03 | Fresenius Medical Care Holdings, Inc. | Methods and systems for patient care |
| WO2007053683A2 (en) * | 2005-11-01 | 2007-05-10 | Fresenius Medical Care Holdings, Inc. | Digital data entry methods and devices |
| AU2009268742C1 (en) * | 2008-07-07 | 2013-11-28 | Pentec Health, Inc. | Nutritive compositions and methods of using same |
| US8698741B1 (en) | 2009-01-16 | 2014-04-15 | Fresenius Medical Care Holdings, Inc. | Methods and apparatus for medical device cursor control and touchpad-based navigation |
| US10799117B2 (en) * | 2009-11-05 | 2020-10-13 | Fresenius Medical Care Holdings, Inc. | Patient treatment and monitoring systems and methods with cause inferencing |
| US9585810B2 (en) | 2010-10-14 | 2017-03-07 | Fresenius Medical Care Holdings, Inc. | Systems and methods for delivery of peritoneal dialysis (PD) solutions with integrated inter-chamber diffuser |
| US10010563B2 (en) * | 2012-11-27 | 2018-07-03 | Terumo Kabushiki Kaisha | Peritoneal dialysis fluid |
| JP7063468B2 (ja) | 2015-09-21 | 2022-05-09 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | がんに対する栄養処置 |
| SE542106C2 (en) * | 2016-08-26 | 2020-02-25 | Atif M Dabdoub | Dietary macro/micronutritional supplement for patients undergoing kidney dialysis |
| CA3084319A1 (en) * | 2017-12-11 | 2019-06-20 | Filtricine, Inc. | Compositions, methods, kits and systems for cancer treatment and metabolic intervention therapy |
| AU2020316017A1 (en) * | 2019-07-19 | 2022-02-17 | Filtricine, Inc. | Compositions, methods, kits and systems for cancer treatment and metabolic intervention therapy and other uses |
| US11278510B2 (en) | 2019-09-05 | 2022-03-22 | Baxter International Inc. | Parenteral nutrition formulation with optimized amino acid and glucose content |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4489097A (en) | 1976-07-28 | 1984-12-18 | The Procter & Gamble Company | Intravenous solutions with antimicrobial agent |
| JPS58500563A (ja) | 1981-04-27 | 1983-04-14 | バクスタ−、トラベノ−ル、ラボラトリ−ズ、インコ−ポレイテツド | グルコ−ス、アミノ酸およびインシユリンを含む透析液 |
| US4491589A (en) | 1982-05-17 | 1985-01-01 | The Trustees Of Columbia University In The City Of New York | Amino acid solutions for parenteral nutrition and methods of formulation and use |
| US4604286A (en) * | 1984-09-17 | 1986-08-05 | Daigo Nutritive Chemicals, Ltd. | Infusion solution for parenteral nutrition |
| JPS6178719A (ja) | 1984-09-25 | 1986-04-22 | Tanabe Seiyaku Co Ltd | 総合輸液剤 |
| JPH0667831B2 (ja) * | 1986-01-13 | 1994-08-31 | 森永乳業株式会社 | 肝物質合成機能障害改善用のアミノ酸組成物 |
| US5122515A (en) | 1990-06-19 | 1992-06-16 | Smith Ross C | Nutrient composition containing dipeptides and method for administering the same |
| US5278149A (en) | 1992-01-17 | 1994-01-11 | New England Deaconess Hospital Corporation | Method of preparing total parenteral nutrition solutions |
| US6380163B1 (en) | 1992-12-22 | 2002-04-30 | Baxter International Inc. | Peritoneal dialysis solutions with polypeptides |
| US5571783A (en) | 1993-03-09 | 1996-11-05 | Clintec Nutrition Company | Composition and method for treating patients with hepatic disease |
| JP2990686B2 (ja) | 1994-11-17 | 1999-12-13 | 田辺製薬株式会社 | 水溶性ビタミンｂ類配合総合輸液 |
| US6852690B1 (en) * | 1995-08-22 | 2005-02-08 | Amylin Pharmaceuticals, Inc. | Method and composition for enhanced parenteral nutrition |
| US6077828A (en) | 1996-04-25 | 2000-06-20 | Abbott Laboratories | Method for the prevention and treatment of cachexia and anorexia |
| SE9703775L (sv) | 1997-10-16 | 1999-04-17 | Pharmalink Baslaekemedel Ab | Framställning av sterial lösningar som innehåller glukos |
| US6610206B1 (en) | 1998-10-20 | 2003-08-26 | Advanced Renal Technologies | Buffered compositions for dialysis |
| US7670491B2 (en) | 1998-10-20 | 2010-03-02 | Advanced Renal Technologies | Buffered compositions for dialysis |
| JP2002045420A (ja) | 2000-08-01 | 2002-02-12 | Terumo Corp | 血液浄化装置、血液浄化方法および透析液パッケージ |
| RU2298428C2 (ru) | 2001-02-07 | 2007-05-10 | Нефрос, Инк. | Способ и устройство для гемодиафильтровального приемно-выводного модуля |
| EP1279400A1 (en) | 2001-07-25 | 2003-01-29 | Target Hit sa | Modifying the fatty acid composition of cell membranes of organs and tissues |
| US7445801B2 (en) | 2002-06-07 | 2008-11-04 | Baxter International Inc. | Stable bicarbonate-based solution in a single container |
| US7323206B1 (en) | 2003-03-04 | 2008-01-29 | B. Braun Medical Inc. | Reagents and methods for all-in-one total parenteral nutrition for neonates and infants |
| AU2004241840B2 (en) * | 2003-05-22 | 2010-02-25 | Otsuka Pharmaceutical Factory, Inc. | Transfusion preparation for peripheral intravenous administration and method of stabilizing vitamin B1 |
| US20050148647A1 (en) | 2003-10-31 | 2005-07-07 | Landry Donald W. | Hemodialysis solutions and uses thereof |
| JP4622311B2 (ja) * | 2004-05-21 | 2011-02-02 | 味の素株式会社 | 末梢静脈投与用輸液 |
| JP2007056013A (ja) | 2005-07-29 | 2007-03-08 | Ajinomoto Co Inc | 透析用補充液 |
| BRPI0614521B8 (pt) | 2005-08-02 | 2021-06-22 | Baxter Healthcare Sa | indicador de oxigênio para uso em produtos médicos |
| JP2007137836A (ja) | 2005-11-21 | 2007-06-07 | Ajinomoto Co Inc | 末梢静脈栄養輸液 |
| DE102006018293A1 (de) * | 2006-04-20 | 2007-10-25 | Fresenius Kabi Deutschland Gmbh | Pädiatrische Aminosäurelösung zur parenteralen Ernäherung |
| JP5316918B2 (ja) | 2006-04-24 | 2013-10-16 | 味の素株式会社 | 透析患者用輸液剤 |
| CN101015501B (zh) * | 2007-02-28 | 2012-03-07 | 华瑞制药有限公司 | 三腔袋包装的脂肪乳、氨基酸和葡萄糖注射液的组合物及其制备方法 |
| WO2008146732A1 (ja) * | 2007-05-25 | 2008-12-04 | Ajinomoto Co., Inc. | 末梢静脈投与用輸液 |
| AU2009268742C1 (en) * | 2008-07-07 | 2013-11-28 | Pentec Health, Inc. | Nutritive compositions and methods of using same |
| WO2010055963A1 (en) | 2008-11-17 | 2010-05-20 | Lee, Jin Tae | Manufacturing method of acetate-free dialysate composition |
-
2010
- 2010-07-30 CA CA2786375A patent/CA2786375A1/en not_active Abandoned
- 2010-07-30 GB GB1211987.1A patent/GB2489163A/en not_active Withdrawn
- 2010-07-30 BR BR112012016435A patent/BR112012016435A2/pt not_active IP Right Cessation
- 2010-07-30 AU AU2010337355A patent/AU2010337355A1/en not_active Abandoned
- 2010-07-30 JP JP2012547991A patent/JP5774603B2/ja active Active
- 2010-07-30 CN CN2010800647187A patent/CN102883729A/zh active Pending
- 2010-07-30 US US12/847,513 patent/US8927505B2/en active Active
- 2010-07-30 EP EP10841409.5A patent/EP2521559A4/en not_active Withdrawn
- 2010-07-30 MX MX2012007704A patent/MX2012007704A/es not_active Application Discontinuation
- 2010-07-30 KR KR1020127020543A patent/KR20120125487A/ko not_active Withdrawn
- 2010-07-30 NZ NZ601027A patent/NZ601027A/en unknown
- 2010-07-30 WO PCT/US2010/043944 patent/WO2011081679A1/en not_active Ceased
- 2010-12-15 GB GB1211991.3A patent/GB2491279A/en not_active Withdrawn
- 2010-12-15 WO PCT/US2010/003192 patent/WO2011081660A1/en not_active Ceased
- 2010-12-15 EP EP10841395.6A patent/EP2521449A4/en not_active Withdrawn
- 2010-12-15 KR KR1020127020550A patent/KR20120104417A/ko not_active Withdrawn
- 2010-12-15 BR BRBR112012016434-1A patent/BR112012016434A2/pt not_active IP Right Cessation
- 2010-12-15 CA CA2786122A patent/CA2786122A1/en not_active Abandoned
- 2010-12-15 CN CN2010800647242A patent/CN102883603A/zh active Pending
- 2010-12-15 JP JP2012547986A patent/JP2013516463A/ja active Pending
- 2010-12-15 NZ NZ601043A patent/NZ601043A/en unknown
- 2010-12-15 AU AU2010337336A patent/AU2010337336A1/en not_active Abandoned
- 2010-12-15 MX MX2012007775A patent/MX2012007775A/es unknown
-
2012
- 2012-07-01 IL IL220715A patent/IL220715A0/en unknown
- 2012-07-03 US US13/541,604 patent/US20120277170A1/en not_active Abandoned
-
2014
- 2014-11-25 US US14/552,725 patent/US20150080323A1/en not_active Abandoned
-
2015
- 2015-05-07 JP JP2015094645A patent/JP2015187112A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013516463A5 (enExample) | ||
| JP2013516464A5 (enExample) | ||
| Bellomo et al. | High protein intake during continuous hemodiafiltration: impact on amino acids and nitrogen balance | |
| CA2574437C (en) | Infusion and injection solution of levodopa | |
| JP6078344B2 (ja) | 免疫グロブリン製剤 | |
| JP4638106B2 (ja) | 医薬的使用のための溶液中における浸透圧剤としての、ｌ−カルニチンおよびそのアルカノイル誘導体の使用 | |
| RU2008143310A (ru) | Способы лечения с применением цитруллина | |
| SE459900B (sv) | Aminosyrakomposition foer behandling av njursvikt | |
| CA2563678A1 (en) | Beneficial effects of increasing local blood flow | |
| RU2013123457A (ru) | Непрерывное введение l-допа, ингибиторов допа-декарбоксилазы, ингибиторов катехол-о-метилтрансферазы и предназначенные для этого композиции | |
| JP2013516463A (ja) | 栄養組成物およびその使用方法 | |
| WO2020001203A1 (zh) | 一种复方氨基酸维生素注射液及其应用 | |
| EP0078832A1 (en) | DIALYSIS SOLUTION CONTAINING GLYCEROL. | |
| TWI445540B (zh) | 抗低體溫組成物 | |
| JP3937423B2 (ja) | アミノ酸含有アルブミン製剤 | |
| CA2416600A1 (en) | Freeze-dried preparation of n-¬o-(p-pivaloyloxybenzenesulfonylamino)benzoyl|glycine monosodium salt tetrahydrate and a process for the maufacture thereof | |
| JP3914585B2 (ja) | マクロファージ一酸化窒素産生亢進剤 | |
| CN102961397B (zh) | 一种脂肪乳注射液和复方氨基酸注射液的药物组合物 | |
| CN102083445A (zh) | 营养组合物及其使用方法 | |
| JP3429327B2 (ja) | 癌用アミノ酸輸液剤 | |
| RU2721605C1 (ru) | Фармацевтическая композиция для парентерального капельного введения | |
| Chan et al. | Ammonia detoxification by continuous venovenous haemofiltration in an infant with urea cycle defect | |
| CN104173343B (zh) | 一种米力农化合物及含有该化合物的药物组合物 | |
| Reddingius et al. | Increase of the Bioavailabllity of Intraperitoneal Erythropoietin in Children on Peritoneal Dialysis by Administration in Small Dialysis Bags | |
| Ruggieri et al. | Does increasing blood pH stimulate protein synthesis in dialysis patients? |